AI and Computer Vision-Assisted Telerehabilitation in Fibromyalgia: The FibroIA 2.0 Trial
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorInstituto Neurociencia Del Dolor
About this trial
Fibromyalgia (FM) is a primary chronic pain condition with an estimated prevalence of 3.3% in Chile. It is characterized by widespread musculoskeletal pain, fatigue, and impaired physical function. Although exercise therapy is considered the first-line intervention, barriers to access and poor adherence limit its effectiveness within the public healthcare system. This study evaluates the effectiveness of an Artificial Intelligence (AI)- and Computer Vision (CV)-assisted telerehabilitation platform called Rehbody. The aim is to determine whether real-time technology-driven feedback can overcome the limitations of traditional face-to-face rehabilitation models by improving disease impact and functional capacity in Chilean patients with fibromyalgia.
Eligibility criteria
Qualifiers
Adults aged 18 years or older, of any sex/gender, with a documented medical diagnosis of fibromyalgia established in primary or secondary healthcare settings according to the American College of Rheumatology (ACR) criteria (Häuser & Fitzcharles, 2018).
Individuals able to understand and complete the self-report questionnaires used in the study.
Individuals with access to a compatible electronic device (smartphone, tablet, or computer) and an internet connection required for participation in the telerehabilitation intervention.
Individuals with basic digital literacy skills, defined as the ability to use electronic devices and interact with commonly used applications.
Disqualifiers
Current participation in another structured therapeutic exercise program, whether supervised or unsupervised.
Moderate to severe functional dependence in activities of daily living, defined as a score <60 on the Barthel Index.
Absolute contraindications to therapeutic exercise, including hypertensive crisis (≥170/110 mmHg), dyspnea at rest, resting tachycardia, or severe glycemic abnormalities (blood glucose >250 mg/dL or <90 mg/dL in individuals receiving insulin therapy).
Severe uncontrolled pain, defined as a score ≥8 on the Numeric Pain Rating Scale (NPRS) at rest.
Trial design
Treatments tested in this trial
- AI Combined (mobility and resistance training)
- AI mobility
Treatment groups
66 Participants
are divided into 3 treatment groupsLocations
This trial has no locations
Sponsors and collaborators
Instituto Neurociencia Del Dolor
Lead sponsor
Universidad San Sebastián
Collaborator
University of Alcala
Collaborator
Source ClinicalTrials.gov